Investor Centre Ltd. (ICU)
ASX 
Summary
SeaStar Medical Holding Corporation (ICU) Q1 2026 Earnings Call Transcript
SeaStar Medical Holding Corporation (ICU) Q1 2026 Earnings Call Transcript
Implied Volatility Surging for ICU Medical Stock Options
Investors need to pay close attention to ICUI stock based on the movements in the options market lately.
Ondine Biomedical shares rise 8% as ICU study shows nasal photodisinfection cuts pneumonia rates by nearly 40%
A peer-reviewed pilot study at a Canadian critical care centre marks the first deployment of nasal photodisinfection in an intensive care setting. Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) shares rose 8% to 11.85p after the company announced a peer-reviewed publication of a pilot study showing its Steriwave nasal photodisinfection therapy reduced pneumonia rates by 39.5% in intensive care unit patients.
Investor Centre Ltd. (ICU) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Investor Centre Ltd. ever had a stock split?
Investor Centre Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Eric Schlorff CEO | ASX Exchange | AU0000108409 ISIN |
| US Country | 19 Employees | - Last Dividend | 5 Jan 2026 Last Split | 28 Oct 2022 IPO Date |
Overview
SeaStar Medical Holding Corporation is a prominent medical device company based in the United States, specifically headquartered in Denver, Colorado. They are at the forefront of developing innovative platform therapies aimed at mitigating the impacts of hyperinflammation on critical organs. The company's core mission revolves around harnessing the body's natural inflammatory response to combat infections and facilitate the healing of damaged tissue. This focus positions SeaStar Medical as a key player in addressing complex medical conditions associated with excessive inflammation.
Products and Services
SeaStar Medical Holding Corporation is engaged in the development of cutting-edge products across various therapeutic areas. These include:
- Pediatric and Adult Acute Kidney Injury on CRRT: Developing treatments to address acute kidney injury (AKI) in both pediatric and adult patients undergoing Continuous Renal Replacement Therapy (CRRT), aiming to improve outcomes and recovery rates.
- Cardiorenal Syndrome in Congestive Heart Failure: Focusing on innovative solutions for patients suffering from cardiorenal syndrome, a condition that complicates congestive heart failure by affecting the heart and kidneys simultaneously, thereby enhancing patient care and management.
- Myocardial Stunning in End Stage Renal Disease: Working on therapies for myocardial stunning, a temporary reduction in the heart's pumping function occurring in patients with end-stage renal disease (ESRD), seeking to improve cardiac function and patient quality of life.
- Hepatorenal Syndrome: Developing treatments for hepatorenal syndrome, a severe condition that develops in patients with advanced liver disease and deteriorates kidney function, aiming to offer hope and new solutions for these critically ill patients.
